Chris Degnan insider trades

Open-market stock purchases and sales by Chris Degnan, Chief Financial Officer at UroGen Pharma Ltd, from SEC Form 4 filings since Jun 19, 2018.

Track record: 0% of 2 scored buys are up 5% or more since purchase, averaging -81%.

Recent trades

DateStockTradeValue
Jan 31, 2026URGN UroGen Pharma LtdBought (not open market)—
Oct 8, 2025URGN UroGen Pharma LtdSold$37.1K
Oct 8, 2025URGN UroGen Pharma LtdBought (not open market)—

Companies traded

  • URGN UroGen Pharma Ltd: 1 sale, last Jan 31, 2026
  • GRTX Galera Therapeutics, Inc: 1 buy, last Mar 13, 2023
  • VRCA Verrica Pharmaceuticals Inc: 1 buy, last Feb 28, 2019

Get free alerts when Chris Degnan files a new trade →